Ant Financial and Nikkei-backed 36Kr has raised just a fifth of its original IPO target and shares took another 10% hit on the first day of trading.

Freee has submitted paperwork for approval to list on the TSE Mothers Market next month, potentially offering exits to more than half a dozen corporates such as Line and Sharp.

SIG-backed drone manufacturer Ehang has filed for an initial public offering in the US with a $100m placeholder figure, with previous reports suggesting an up-to $500m target.

The Celgene and GV-backed small molecule drug developer floated at the bottom of its range, raising less than half the target it set last week.

University of Pennsylvania spinout Cabaletta has gone public after raising $74.8m in an initial public offering on the Nasdaq Global Select Market.

Tasly and Genexine-backed I-Mab has filed to raise up to $100m that will fund development of its autoimmune disorder and cancer drugs.

The apartment rental services provider, which counts Ant Financial, UCommune and Bertelsmann as investors, has filed for a $100m IPO on the New York Stock Exchange.

The Takeda-backed gastrointestinal disease therapy developer has boosted its initial public offering to $209m after its shares rose 23% post-flotation.

Xiaomi is set to achieve an exit after audio content platform Lizhi filed for an initial public offering in the US that is slated to raise up to $100m.

The Novo and Novartis-backed company, which is developing drugs to make radiotherapy less harmful, is set to raise between $70m and $80m.